The FDA has approved jardiance for the treatment of type 2 diabetes, it was announced today. Jardiance, which is also known as empagliflozin, is used alongside exercise and a balanced diet to help improve glycemic control in adults with type 2 diabetes.
Jardiance works by preventing the re-absorption of blood sugar by the kidneys and increases glucose excretion. It also lowers the blood sugars of patients with type 2 diabetes when their glucose levels are elevated.
Commenting in a press release, Curtis J. Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research, said:
"Jardiance provides an additional treatment option for the care of patients with type 2 diabetes."
“It can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of diabetes.”
Nearly 5,000 patients with type 2 diabetes took part in the trial and it was found that the drug effectively improved the AIc levels when compared to a placebo.
Studies have been conducted into using jardiance as a standalone treatment for type 2 diabetes and it has also been used in conjunction with other forms of drugs such as metformin.
However, the drug can't be taken by patients with type 1 diabetes, patients on kidney dialysis, end stage renal disease, or by patients with high levels of ketones in their blood or urine.
The original press release can be found here.
Jardiance works by preventing the re-absorption of blood sugar by the kidneys and increases glucose excretion. It also lowers the blood sugars of patients with type 2 diabetes when their glucose levels are elevated.
Commenting in a press release, Curtis J. Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research, said:
"Jardiance provides an additional treatment option for the care of patients with type 2 diabetes."
“It can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of diabetes.”
Nearly 5,000 patients with type 2 diabetes took part in the trial and it was found that the drug effectively improved the AIc levels when compared to a placebo.
Studies have been conducted into using jardiance as a standalone treatment for type 2 diabetes and it has also been used in conjunction with other forms of drugs such as metformin.
However, the drug can't be taken by patients with type 1 diabetes, patients on kidney dialysis, end stage renal disease, or by patients with high levels of ketones in their blood or urine.
The original press release can be found here.
